1.
Mult Scler Relat Disord
; 9: 122-4, 2016 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27645358
RESUMO
Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been rarely reported during Natalizumab treatment. We believe that clinicians need heightened awareness of these infections in view of the risks of serious complications.